Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10.

Molecular mechanisms of transformation by the BCR-ABL oncogene.

Author information

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.

Abstract

The BCR-ABL oncogene is generated by the Philadelphia chromosome (Ph) translocation, fusing the BCR gene to the ABL gene. The BCR-ABL fusion protein has elevated ABL tyrosine kinase activity that is critical for transformation of hematopoietic cells. Chronic myelogenous leukemia (CML) cells transformed by BCR-ABL show reduced growth factor requirements and apoptosis, as well as enhanced viability and altered adhesion. The elevated ABL kinase activity leads to chronic activation of signaling pathways that are required for all aspects of transformation. Progression of the disease from chronic phase to blast crisis correlates with additional cytogenetic alterations that are likely to contribute to the failure of traditional therapy. This review describes molecular mechanisms that are thought to be important for transformation by the BCR-ABL oncoprotein and points at pathways for targeted drug development in the treatment of CML.

Copyright 2003 Elsevier Inc. All rights reserved.

PMID:
12783368
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk